Latest News

Latest News

Rethinking Biologics Plants to Earn Attractive Returns

Rethinking Biologics Plants to Earn Attractive Returns

The rapid growth of biologics and other advanced therapeutic modalities is transforming pharmaceutical R&D and manufacturing. From monoclonal antibodies and oligonucleotides to cell and gene therapies, these products introduce a level of process complexity,...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

The Financial Infrastructure Behind Healthcare Innovation

The Financial Infrastructure Behind Healthcare Innovation

Healthcare is changing faster than I have ever seen it change, and the revenue cycle has to keep pace. We are talking about AI, new treatments, new technology, new specialties and entirely new ways of delivering care. All of that is exciting, and much of it has the...

read more
When the Model Is Confident and the Patient Is Not

When the Model Is Confident and the Patient Is Not

It is 2:07 a.m. in the emergency department. The waiting room is thin. The hallway is not. A middle-aged man looks pale. His vitals sit in the green band. A clinical decision support tile on the chart says low risk with a high confidence score. His wife keeps saying...

read more
China Out-Licensing Deals 2026: The Billion-Dollar Tracker

China Out-Licensing Deals 2026: The Billion-Dollar Tracker

In the first half of 2026, China’s innovative drug licensing deals reached $106.3bn, according to VBInsight data published by VCBeat. That total covers inbound and outbound deals. That compares with $135.7bn for the whole of 2025 on the same provider’s count. This...

read more
Weekly News Roundup | 28 September 2026

Weekly News Roundup | 28 September 2026

Life science news 28 September 2026: four US drug approvals, three UK developments and two global R&D deals. The FDA approved Atebrioz, the third treatment for fibrodysplasia ossificans progressiva, and AbbVie’s Parkinson’s drug Juvmo. The MHRA approved...

read more
Multi-Cancer Early Detection Test Divides FDA Advisers

Multi-Cancer Early Detection Test Divides FDA Advisers

A United States advisory panel has recommended approval of a multi-cancer early detection blood test. The Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee met on 23 September 2026. It reviewed GRAIL’s Galleri test. The assay reads...

read more
The Financial Infrastructure Behind Healthcare Innovation

The Financial Infrastructure Behind Healthcare Innovation

Healthcare is changing faster than I have ever seen it change, and the revenue cycle has to keep pace. We are talking about AI, new treatments, new technology, new specialties and entirely new ways of delivering care. All of that is exciting, and much of it has the...

read more
When the Model Is Confident and the Patient Is Not

When the Model Is Confident and the Patient Is Not

It is 2:07 a.m. in the emergency department. The waiting room is thin. The hallway is not. A middle-aged man looks pale. His vitals sit in the green band. A clinical decision support tile on the chart says low risk with a high confidence score. His wife keeps saying...

read more
China Out-Licensing Deals 2026: The Billion-Dollar Tracker

China Out-Licensing Deals 2026: The Billion-Dollar Tracker

In the first half of 2026, China’s innovative drug licensing deals reached $106.3bn, according to VBInsight data published by VCBeat. That total covers inbound and outbound deals. That compares with $135.7bn for the whole of 2025 on the same provider’s count. This...

read more
Weekly News Roundup | 28 September 2026

Weekly News Roundup | 28 September 2026

Life science news 28 September 2026: four US drug approvals, three UK developments and two global R&D deals. The FDA approved Atebrioz, the third treatment for fibrodysplasia ossificans progressiva, and AbbVie’s Parkinson’s drug Juvmo. The MHRA approved...

read more
Multi-Cancer Early Detection Test Divides FDA Advisers

Multi-Cancer Early Detection Test Divides FDA Advisers

A United States advisory panel has recommended approval of a multi-cancer early detection blood test. The Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee met on 23 September 2026. It reviewed GRAIL’s Galleri test. The assay reads...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Online Prescribing Is Moving Faster Than Regulation

Online Prescribing Is Moving Faster Than Regulation

Online prescribing has moved from being a relatively niche part of healthcare to an increasingly established route through which patients access treatment. That change brings clear benefits. Patients can seek treatment discreetly, access clinicians without travelling,...

read more
Clinical Trials Roundup | 25 September 2026

Clinical Trials Roundup | 25 September 2026

The clinical trial results 25 September 2026 span Sjögren’s, urticaria, IgA nephropathy, obesity, cutaneous lupus and Alzheimer’s psychosis. Amgen’s dazodalibep met its primary endpoint in systemic Sjögren’s disease. Celldex’s barzolvolimab met its primary and all key...

read more
Rethinking the Office: The Need for Healthier Buildings

Rethinking the Office: The Need for Healthier Buildings

For property owners, management companies, and business leaders, few sights are more unwelcome than an empty office building. Indoor air quality may be part of the answer to filling it. In the post-pandemic era, the home office has replaced the traditional workplace...

read more
Surgical Site Infections Can Consume Up to 75 Staff Hours

Surgical Site Infections Can Consume Up to 75 Staff Hours

Surgical site infections can consume up to 75 staff hours and displace three operations, research finds A single surgical site infection (SSI) can consume an estimated 45 to 75 additional hours of healthcare staff time and create downstream demands equivalent to the...

read more
The New Launch Model for the Agentic Era

The New Launch Model for the Agentic Era

Creating brand value when clinical information is no longer a differentiator The Life Sciences industry is undergoing seismic shifts: expanding drug pipelines, compressed launch timelines, and changing healthcare provider (HCP) and human capital expectations. HCPs...

read more

Further News

Why US Federal Legislation Is the Best Chance to Rein In PBMs

Federal legislation is the best opportunity to compel pharmacy benefit managers (PBMs) to change. Neither a major Federal Trade Commission (FTC) settlement nor reforms at the state level have fixed market distortions. But the upcoming US midterm elections in November...

The Evidence Problem in Cosmetic Actives: Why In-Vitro Data Is Not Enough

As Head of R&D at a Swiss cosmetics laboratory, I read a lot of the evidence behind the cosmetic actives that brands ask us to put in their formulas. The same pattern keeps turning up. A well-cited in-vitro mechanism gets marketed as if it were a proven clinical...

Who Owns Ilofotase Alfa Now? Inside Ambrose’s AM-Pharma Deal

Ilofotase alfa now belongs to Ambrose Healthcare, a UK-headquartered rare disease company. On 20 October 2026, Ambrose said it had acquired 100 per cent of the shares of AM-Pharma. The Dutch company, based in Utrecht, developed the drug. The deal is complete rather...

RNA-LNP Development: Creative Biolabs Links Design, Formulation & Analysis

RNA delivery research is moving beyond conventional lipid nanoparticle (LNP) formulation toward a more systematic understanding of how lipid chemistry, particle organization, and intracellular trafficking influence delivery performance. As researchers confront...

Bepirovirsen NHS Access: Will UK Hepatitis B Patients Get Hibsago?

Bepirovirsen NHS access is undecided, because the drug has no UK marketing authorisation. GSK said the US FDA approved bepirovirsen, branded Hibsago, for chronic hepatitis B on 20 October 2026. NHS patients cannot expect routine access until the MHRA authorises it and...

Pediatric Eye Injuries: Severity, Referral and Permanent Vision Loss

A child's vision is one of their most important developmental assets. Sight shapes how children learn, play, read, and connect with the world around them, and unlike many other aspects of health, vision loss caused by pediatric eye injuries can have consequences that...

Who Notices When a Clinical Model Drifts?

Most clinical prediction tools get one big exam. Someone pulls a retrospective cohort, runs the numbers, shows a committee a curve, and the tool goes live. After that the exam rarely gets repeated, so model drift can go unnoticed. The emergency department keeps...

UK Lab Space in 2026: Record Vacancy, Regional Squeeze

UK lab space vacancy hit a record 14.3% in 2026, yet regional parks report labs near capacity. Find out why the mismatch matters.

    Dostarlimab Rectal Cancer: Will the NHS Offer It Outside Wales?

    Dostarlimab rectal cancer won FDA accelerated approval on 19 October 2026. Wales supports use; NICE and the MHRA have yet to decide.

      When the AI Inside a Medical Device Belongs to Someone Else

      Medical device manufacturers have long relied on third-party technology. Generative AI, however, presents new challenges for manufacturers of AI medical devices, who may have little influence over how the external model is developed. The technology may be outside of...

      Redrawing the Limits of “Undruggable” Proteins

      For most of modern target-based drug discovery's history, many biologically important targets have been sidelined as undruggable proteins: structural scaffolds and transcription factors with no active site to inhibit, proteins presenting flat surfaces with no pocket...

      Roche Hansoh ADC Deal: What Does Roche Get for $400 Million?

      Roche pays Hansoh $400 million upfront and $110 million on the first anniversary for ex-Greater China rights to a preclinical ADC portfolio.

        Want to Be Part of the Next Chapter in Life Sciences Media?

         

        LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

         

         

        Don’t wait for the media to pick up your story. Be the media.

        See More Articles

        Want to Be Part of the Next Chapter in Life Sciences Media?

         

        LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

         

         

        Don’t wait for the media to pick up your story. Be the media.